Fortrea Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Fortrea Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Fortrea Holdings Inc FTRE.OQ reported quarterly adjusted earnings of 23 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 19 cents. The mean expectation of eleven analysts for the quarter was for earnings of 18 cents per share. Wall Street expected results to range from 14 cents to 23 cents per share.
Revenue fell 4.5% to $678.20 million from a year ago; analysts expected $647.46 million.
Fortrea Holdings Inc's reported EPS for the quarter was a loss of 14 cents.
The company reported a quarterly loss of $13.2 million.
Fortrea Holdings Inc shares had risen by 19.0% this quarter and gained 20.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.9% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Fortrea Holdings Inc is $18.50, about 11.9% below its last closing price of $20.70
This summary was machine generated from LSEG data July 29 at 02:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 0.18 | 0.23 | Beat |
Mar. 31 2026 | 0.05 | 0.16 | Beat |
Dec. 31 2025 | 0.16 | 0.09 | Missed |
Sep. 30 2025 | 0.15 | 0.12 | Missed |
Recent news on Fortrea Holdings
See all newsFortrea Q3 revenue beats expectations on bookings momentum, guidance raised
Brief: Fortrea And Omico Collaboration To Advance Biomarker-Led Oncology Drug Development
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler
Brief: Fortrea Completes Acquisition Of The Early Phase Services Division From Worldwide Clinical Trials
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike